Table 3.
Efficacy of remdesivir in outpatients at high risk of progression to severe COVID-19 in the phase III PINETREE trial [47]
| Endpoints | REMa (n = 279) | PL (n = 283) | HR/RR (95% CI) |
|---|---|---|---|
| COVID-19-related hospitalization or death from any cause (% of pts) | |||
| Day 28b | 1* | 5 | HR 0.13 (0.03–0.59) |
| Day 14 | 1 | 5 | HR 0.13 (0.03–0.59) |
| COVID-19-related medically attended visit or death from any cause (% of pts) | |||
| Day 14 | 1 | 8 | HR 0.10 (0.02–0.43) |
| Day 28 | 2 | 8 | HR 0.19 (0.07–0.56) |
| Hospitalization for any cause by day 28 (% of pts) | 2 | 6 | HR 0.28 (0.10–0.75) |
| Death from any cause by day 28 (% of pts) | 0 | 0 | |
| Alleviation of COVID-19 symptomsc by day 14 (% of pts) | |||
| Questionnaire completed before infusion on day 1 | 35 | 25 | RR 1.41 (0.73–2.69) |
| Questionnaire completed on day 1, either before or after infusion | 36 | 20 | RR 1.92 (1.26–2.94) |
HR hazard ratio, PL placebo, pts patients, REM remdesivir, RR rate ratio
*p = 0.008 vs PL
aIntravenous infusion of 200 mg on day 1 and 100 mg on days 2 and 3
bPrimary endpoint
cMild or absent symptoms on the Influenza Patient-Reported Outcome (FLU-PRO) Plus questionnaire, adapted for pts with COVID-19